Data from Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing

Abstract

<div>AbstractPurpose:<p>The addition of immune checkpoint blockade (ICB) to platinum/etoposide chemotherapy changed the standard of care for small cell lung cancer (SCLC) treatment. However, ICB addition only modestly improved clinical outcomes, likely reflecting the high prevalence of an immunologically “cold” tumor microenvironment in SCLC, despite high mutational burden. Nevertheless, some patients clearly benefit from ICB and recent reports have associated clinical responses to ICB in SCLC with (i) decreased neuroendocrine characteristics and (ii) activation of NOTCH signaling. We previously showed that inhibition of the lysine-specific demethylase 1a (LSD1) demethylase activates NOTCH and suppresses neuroendocrine features of SCLC, leading us to investigate whether LSD1 inhibition would enhance the response to PD-1 inhibition in SCLC.</p>Experimental Design:<p>We employed a syngeneic immunocompetent model of SCLC, derived from a genetically engineered mouse model harboring <i>Rb1/Trp53</i> inactivation, to investigate combining the LSD1 inhibitor bomedemstat with anti-PD-1 therapy. <i>In vivo</i> experiments were complemented by cell-based studies in murine and human models.</p>Results:<p>Bomedemstat potentiated responses to PD-1 inhibition in a syngeneic model of SCLC, resulting in increased CD8<sup>+</sup> T-cell infiltration and strong tumor growth inhibition. Bomedemstat increased MHC class I expression in mouse SCLC tumor cells <i>in vivo</i> and augmented MHC-I induction by IFNγ and increased killing by tumor-specific T cells in cell culture.</p>Conclusions:<p>LSD1 inhibition increased MHC-I expression and enhanced responses to PD-1 inhibition <i>in vivo</i>, supporting a new clinical trial to combine bomedemstat with standard-of-care PD-1 axis inhibition in SCLC.</p></div>